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ABSTRACT 
Despite a historical focus on neurally-mediated interoceptive signaling mechanisms, 
humoral (and even cellular) signals also play an important role in communicating bodily 
physiological state to the brain. These signaling pathways can perturb neuronal structure, 
chemistry and function leading to discrete changes in behavior. They are also increasingly 
implicated in the pathophysiology of psychiatric disorders. The importance of these humoral 
signaling pathways is perhaps most powerfully illustrated in the context of infection and 
inflammation. Here we provide an overview of how immune activation of neural and 
humoral interoceptive mechanisms interact to mediate discrete changes in brain and 
behavior and highlight how activation of these pathways at specific points in neural 
development may predispose to psychiatric disorder. As our mechanistic understanding of 
these interoceptive pathways continues to emerge it is revealing novel therapeutic targets, 
potentially heralding an exciting new era of immunotherapies in psychiatry. 
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INTRODUCTION 
Inflammation is increasingly implicated in the pathogenesis of many common psychiatric 
disorders. Similar to other physiological processes, interoceptive pathways play a critical role 
in communicating immune state to the brain. Within the body, the immune system acts as a 
distributed chemosensory system using diverse pattern-recognition receptors (PRRs) to 
detect the presence of pathogen- (PAMP) and tissue stress or damage- (DAMP) associated 
molecular patterns. On activation, immune cells release immune and inflammatory 
mediators, notably cytokines. Parallel neural, humoral and cellular interoceptive pathways 
then communicate these changes in immune state to the brain to trigger alterations in 
mood and cognition, motivation, and neurovegetative processes (1-3). However, immune 
activity is not solely regulated in the periphery. Top-down influences from the brain can 
dampen peripheral inflammation via hypothalamic release of CRH (corticotrophin-releasing 
hormone) and the vagus nerve inflammatory reflex (4). Conversely, sympathetic projections 
to lymphoid tissue, including the bone marrow, lymph nodes, and spleen can prime immune 
responses to actual or perceived environmental threats (5-7).  
Typically, inflammation is short-lived and these adaptive changes in behavior that serve to 
reprioritize behavioral responses towards the insult rapidly return to baseline (8). However, 
when inflammation is severe, becomes chronic (9), or occurs during critical developmental 
windows (10) or on a background of neurodegeneration (11) or chronic severe stress,  
prolonged activation of interoceptive pathways and consequent neurochemical changes can 
precipitate long-standing maladaptive neurobiological and behavioral changes that are 
implicated in the pathophysiology of many common psychiatric disorders.  
Recent progress in understanding the molecular and cellular processes underlying 
bidirectional immune-brain interactions is revealing the complex nature of interoceptive 
signaling of immunity. For example, it is now recognized that during periods of severe stress 
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increased sympathetic outflow can result in sustained splenic enlargement and production 
of monocytes with enhanced migratory and pro-inflammatory phenotypes in rodents (7, 12). 
Historically, only the adaptive immune system has been considered capable of retaining a 
‘memory’ of past events. However, these persistent immunological changes appear to 
provide a peripheral, bodily index of prior stress exposure that accords with recent 
recognition of wider innate immune system memory (13). Supporting this, subsequent stress 
exposure (even when sub-threshold) results in significant trafficking of these ‘pro-
inflammatory’ monocytes to the brain where they then differentiate into tissue 
macrophages to promote inflammatory signaling and amplify behavioral stress responses 
(7). Findings such as this are highlighting the importance of cellular, as well as more 
conventional humoral and neural pathways and underscore the need to broaden our 
conceptualization of interoceptive signaling. As we discuss below, these developments are 
also beginning to reveal novel therapeutic drug targets and allow a reappraisal of how some 
established therapies might be exerting therapeutic efficacy. 
 
HOW IS INFLAMMATION COMMUNICATED TO THE BRAIN? 
Visceral afferents: Similar to the signaling of other physiological processes, central 
communication of peripheral inflammation appears dependent on interoceptive visceral 
afferents travelling in the vagus and other autonomic nerves (14). These afferents express 
cytokine-binding sites (15). Antigen presenting cells accumulate around site/s of 
inflammation then signal to visceral afferents using cytokine-dependent (16) and 
independent mechanisms (17). Signaling via this neural interoceptive pathway is rapid, 
inducing c-Fos expression in the solitary nucleus (NTS) (the primary projection nucleus of the 
vagus) and higher projection regions within an hour of challenge in rats (14). Human 
functional imaging studies demonstrate activation of a similar neurally-mediated 
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interoceptive pathway (projecting to ventromedial posterior thalamus and then 
mid/posterior insula) within 2-3 hours of inflammatory challenge (18-20) (Figure 1). 
Projections from the NTS to the vagal dorsal motor nucleus and nucleus ambiguous initiate 
reflex responses including the inflammatory reflex, which regulate the magnitude of innate 
immune responses (4). Conversely, projections to the caudo- and then rostro-ventrolateral 
medulla influence sympathetic outflow. Ascending projections to the hypothalamus, 
hippocampus, extended amygdala, striatum, cingulate, insula and higher cortical areas 
underpin discrete changes in behavior (17, 21) (See Figure 2 for ‘circuit’ diagram). Though 
beyond the scope of the current review, a number of recent approaches have applied 
principles of hierarchical predictive coding and/or Bayesian active inference to information 
processing within these regions to provide a theoretical framework linking them to discrete 
changes in behavior and/or psychopathological features (22-24) 
Humoral pathways: Circulating inflammatory mediators also activate humoral interoceptive 
pathways. Some mediators can access the brain directly via the sensory circumventricular 
organs located in the walls of the third and fourth ventricles (25). In these regions loops of 
fenestrated capillaries surrounded by large perivascular spaces facilitate a dramatic increase 
in surface area and permeability (26). This, together with dense receptor expression, enables 
detection of large circulating molecules including those that provide information about 
systemic inflammation. While the circumventricular organs are specialized for the detection 
of low concentrations of circulating factors, some inflammatory mediators e.g. interleukin 
(IL)-6, interferon (IFN)-α and immune cells (e.g. stress-induced monocytes) can also enter 
the central nervous system (CNS) in small quantities in other regions to exert direct 
functional effects (7, 27). Perhaps the best illustration of humoral interoception is 
inflammation-induced pyrexia. Here, cytokines (particularly IL-6) act directly on the brain 
endothelium to trigger prostaglandin E2 release which acts as a pyrogen at the hypothalamic 
median preoptic nucleus (28). 
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Cellular pathways: Monocytes and Microglia: As highlighted earlier, direct monocyte 
trafficking also provides a cellular interoceptive pathway for communicating immune state 
to the brain (7). Though typically low during health, monocyte trafficking increases 
significantly following severe stress in rodents, and appears to serve as a mechanism for 
amplifying behavioral stress responses given a history of previous sustained threat (7). 
Transduction of interoceptive signaling of inflammation also involves microglia (specialized 
brain macrophages with distinct phylogenetic origins) (29). In health, microglia show highly 
dynamic behavior, expanding and retracting branched ramifications to continuously sample 
neighboring cells and extracellular space (30). In this ‘resting’ state they are implicated in 
synaptic pruning (31), a process critical for neural plasticity and learning. Like peripheral 
macrophages, microglia exist in multiple ‘activated’ forms associated with distinct changes in 
morphology and secretory profile that can alter local neuronal and endothelial function (32). 
Within the brain, activation of microglia occurs in response to diverse danger-associated 
homeostatic changes e.g. ischemia. However, it is also observed following exposure to 
repeated environmental stresses, which is likely mediated via activity-dependent release of 
ATP in response to neuronal glutamate signaling (33).  
Important to their role in interoceptive signaling, microglia are also sensitive to systemic 
danger signals including peripheral inflammation. In this context, microglial activation likely 
occurs through activation of interoceptive pathways that involve passage of cytokines across 
the BBB (34), release of prostaglandin E2 by perivascular and endothelial cells in response to 
intravascular inflammation (35) or entry of stress-sensitive monocytes into the CNS (33). In 
rodents, peripheral inflammation results in rapid activation of microglia within the 
circumventricular organs, leptomeninges, and choroid plexus, which release tumor necrosis 
factor (TNF) to trigger a cascade of microglial activation that spreads across the brain (36). 
Translocator protein (TSPO) PET (a marker of activated microglia) has illustrated a similar 
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pattern of widespread microglial activation following LPS-induced peripheral inflammation 
in humans (37).  
Below, we describe how signaling via these pathways can result in regional disturbances in 
neuronal metabolism, neurotransmitter release and brain activity associated with discrete 
features of psychopathology.  
 
INTEROCEPTIVE SIGNALING OF INFLAMMATION IN PSYCHIATRIC DISORDERS 
MOOD DISORDERS 
Arguably the strongest evidence implicating interoceptive signaling of inflammation to 
psychiatric illness is for mood disorders. Stress, particularly in early life, is a major 
vulnerability factor for mood disorders and has been linked to sustained inflammation in 
human meta-analysis (38). Preclinical studies link this stress vulnerability to bi-directional 
interactions between the brain and immune system. Specifically, repeat exposure to severe 
social stress (using the repeated social defeat (RSD) model) activates fear-associated neural 
circuitry. It also increases sympathetic outflow which acts on the bone marrow and spleen to 
bias myeloid precursor cells (particularly monocytes) toward a glucocorticoid resistant and 
primed lineage (33). Sustained glutamatergic activity within brain regions mediating fear 
responses also triggers local microglial priming, likely through activity-dependent ATP 
release from astrocytes binding to microglial P2X7 receptors (7).  
Interoceptive pathways link these central and peripheral immune changes and make a 
powerful contribution to the cumulative effects of repeated stress. For example, in addition 
to release of inflammatory mediators including IL-1 (which modify neuronal function and 
disrupt monoamine synthesis) (33, 39), activated microglia also release chemokines (e.g. 
CCL2 and CX3CL1), which trigger homing of monocytes primed by previous stress exposure 
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from the circulation into stress-associated brain regions (33). Pro-inflammatory cytokine 
release from primed monocytes that have entered the CNS then further contribute to the 
maladaptive effects of chronic stress. This cellular interoceptive signaling pathway also 
appears to underlie the process of ‘stress-sensitization’ whereby previously stressed animals 
show a heightened propensity to maladaptive stress responses to later sub-threshold 
stressors (12, 40) (Figure 3).  
Interoceptive signaling of inflammation also plays a role in human depression. Cumulative 
meta-analyses now provide convincing evidence for raised peripheral inflammatory markers 
particularly IL-6 and CRP in a subset of depressed patients (41). Gene expression analyses 
also implicate IL-6, TNF and interferon-alpha (IFN-α) signaling pathways (42-44). This 
increase in peripheral inflammatory markers is linked to disturbances in brain function. For 
example, depressed patients with raised CRP show impairments in the functional 
connectivity of ventral striatum and medial prefrontal reward and motivation processing 
areas (39). Recently, depression has also been linked to CNS inflammation, with widespread 
increases in activated microglia observed using TSPO PET (45). Perhaps the most powerful 
evidence supporting an etiological role for inflammation comes from patients receiving 
prolonged IFN-α therapy, up to 50% of whom develop major depressive episodes (46, 47).  
Here, IFN-α appears to trigger depression-associated behavioral changes through activation 
of humoral and, to a lesser extent, neural interoceptive pathways (48). In humans, 
therapeutically administered IFN-α is observed in the CSF (49). In rodents, peripheral IFN-α 
rapidly up-regulates interferon-sensitive gene expression within predominantly sub-cortical 
structures (50, 51). Together, these studies support rapid activation of humoral 
interoceptive signaling pathways. Within the brain parenchyma, IFN-α shows a marked 
predilection for subcortical structures including the basal ganglia and hippocampus (51, 52). 
This is reflected in imaging studies of patients receiving IFN-α for the treatment of hepatitis-
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C who show changes in striatal glucose metabolism, dopamine uptake, glutamate (53, 54) 
and microstructural changes in striatal water distribution (48, 55). The functional 
significance of these striatal changes is supported by significant correlations with IFN-α-
induced changes in motivation and/or fatigue (53, 54).  
Pro-inflammatory cytokines also increase expression of the enzyme indoleamine 2,3-
dioxygenase (IDO) shunting tryptophan metabolism away from serotonin synthesis into the 
kynurenine pathway. This results in the production of a number of neuroactive metabolites 
including the neuroprotective NMDA receptor antagonist, kynurenic acid (KynA) as well as 
the potentially neurotoxic NMDA receptor agonists, 3-hydroxykynurenine (3HK) and 
quinolinic acid (QA) both of which can influence glutamatergic signaling. During IFN-α 
treatment, CSF concentrations of each of these metabolites increases, with increases in 
KynA and QA correlating with depressive symptoms (56). Under inflammatory conditions, 
brain production of QA tends to overshadow that of KynA (57) such that the ratios KynA/3HK 
and KynA/QA can provide a sensitive index of the competing effects of these neuroactive 
metabolites. Several investigators have now reported reduced KynA/QA in major depressive 
disorder (MDD) as well as bipolar and schizoaffective disorder, which is additionally linked to 
altered hippocampal and medial prefrontal cortex volume/ function (58-61). These studies 
illustrate putative mechanisms through which activation of interoceptive signaling pathways 
can lead to neurochemical change and shifts in behavior. 
 
SCHIZOPHRENIA AND AUTISM SPECTRUM DISORDER  
Like mood disorders, schizophrenia and autism spectrum disorders (ASD) have been 
associated with raised circulating pro-inflammatory cytokines in cohort studies (62). 
However, unlike depression, emerging evidence suggests that this pro-inflammatory 
phenotype may have its origins in early development. Epidemiological work has long 
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identified in-utero infection as a risk factor for development of schizophrenia in offspring 
(63). Maternal exposure to infection has also been linked with autism, with a recent 
prospective study reporting a dosage effect such that three or more episodes of fever during 
the second trimester raised the risk of having a child with ASD threefold (64). 
Preclinical studies of maternal immune activation, (typically modeled with the viral mimetic 
polyinosinic:polycytidylic acid (poly I:C)), lend support to epidemiological studies by showing 
sustained abnormalities in rodent analogues of the repetitive movements and deficits in 
social behavior, sensory gating and cognition that characterize autism and/or schizophrenia 
(65). Post-mortem and animal imaging studies further show that maternal immune 
activation leads to changes in synaptic connectivity and neuroplasticity that may manifest as 
changes in cortical thickness and brain volume (65). The mechanisms underpinning this 
dysregulation of neural development remain to be fully characterized, though suggest that 
even before birth interoceptive-signaling pathways may play a role in human 
psychopathology. 
Since most pathogens do not directly infect the fetus, early infection is thought to impair 
normal brain development via activation of the maternal immune system. Preclinical models 
indicate that maternal cytokines are necessary for development of disease in offspring, 
though whether cytokines cross the placenta or act indirectly remains unclear (65). Either 
way, maternal immune activation appears to initiate changes in gene expression that affect 
neuronal migration, synaptic pruning, and myelination. Here again microglia may play a role 
since these cells are involved in multiple aspects of brain development, especially synaptic 
pruning (66). Fetal oligodendroglia may also be impacted: in a recent study, poly(I:C) 
administration resulted in down-regulation of genes involved in myelination in the medial 
PFC and nucleus accumbens that correlated with spatial memory deficits in the offspring. 
Further, the viral mimetic group had a greater myelin water fraction in the cortex (including 
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insula), hippocampus, and cerebellum, potentially indicating changes in the microstructure 
of the myelin sheath (67). Nonetheless, since most maternal infections do not directly lead 
to schizophrenia or ASD, subsequent “hits” taking the form of stress or adult-onset 
infections may be necessary for the manifestations of psychiatric disorders (65, 68). 
Analogous to what is described in chronic stress, these second “hits” may dysregulate an 
already sensitized or ‘primed’ immune system leading to the neural and behavioral 
abnormalities characteristic of schizophrenia and ASD. A case in point is microglia which are 
known to be primed by infection (69), are increased in density in schizophrenia post-mortem 
(70), and show a shift towards a primed morphology in ASD (71). 
 
LINKING INTEROCEPTION TO DISCRETE BEHAVIORAL PHENOTYPES 
Most human studies addressing how interoceptive signaling of inflammation contributes to 
discrete dimensional psychiatric constructs have adopted an experimental medicine 
approach using a variety of inflammatory challenges. Some use vaccines (19) or inhaled 
antigens (72) to induce mild increases in inflammatory cytokines similar to those observed in 
depression; others low-dose lipopolysaccharide (LPS) to induce more robust pro-
inflammatory responses (18, 73). Despite the variety of inflammation-induction techniques 
used, increases in insula activity are commonly observed, consistent with activation of a 
neurally mediated interoceptive pathway (Figure 1). Interestingly, many of these studies also 
link changes in insula activity to shifts in subjective experience (18-20), particularly fatigue, 
consistent with the proposed role of the insula in subjective experiential states (74). 
 
MOTIVATION 
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During infection, interoceptive signaling of inflammation rapidly reorients motivation, 
impairing reward-related behavior and increasing sensitivity to punishments, particularly 
pain (8). This serves to prioritize whole organism responses towards fighting the infecting 
agent. However, if sustained may predispose to the development of MDD or chronic pain 
syndromes (25).  
A wealth of studies has identified a critical role for the  ventral striatum in mammalian 
reward processing and appetitive motivation (see (75) and citing articles). Within the 
midbrain, dopaminergic cells encode a reward prediction error, with their firing rate 
increasing (or decreasing) if rewards are higher (or lower) than predicted (76). Projections to 
the ventral striatum serve to update value estimates for available options and bias behavior 
to maximize long-term future reward. Recent studies have started to clarify how 
interceptive signaling of inflammation can disrupt these processes. For example, peripheral 
inflammation results in an acute reduction in ventral striatal encoding of reward prediction 
error signal (77). It is also linked to disrupted presynaptic dopamine synthesis in humans (53) 
and reduced CSF concentrations of the dopamine metabolite homovanillic acid in monkeys 
(78). Cytokine associated reduction in dopamine synthesis may also be achieved by reducing 
CNS concentrations of tetrahydrobiopterin, an essential dopamine synthesis cofactor  (79).  
Alternately, dopamine neurotransmission may be reduced by either activation of the 
tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) (leading to the formation 
of neurotoxic kynurenine metabolites) (25) or by increasing expression of reuptake 
transporters (79-82). Together, these implicate humoral interoceptive pathways in the 
reward-related motivational impairment characteristic of inflammation. 
Though most studies of motivation have focused on reward, some brain areas implicated in 
neural interoceptive signaling (e.g. Insula) are also linked to choices associated with 
potential losses (21, 74, 83, 84). Specifically, anterior insula cortex appears to encode a 
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punishment prediction error signal linked to learning to avoid punishing outcomes (83). In 
patients with selective insula lesions this signal is disrupted and punishment sensitivity 
impaired (85). Conversely, during inflammation when interoceptive signaling is increased, 
insula encoding of punishment prediction error and sensitivity to punishments are enhanced 
(77). This suggest that relative sensitivity to reward and punishments can be dynamically 
modulated as a function of interoceptive signaling of inflammation, flexibly enhancing loss 
minimization during threats (like infection) but maximizing responses to gains during health. 
Though potentially beneficial during acute infections when substantial metabolic resources 
are diverted towards fighting infection, when inflammation is chronic this mechanism may 
underlie the maladaptive motivational changes observed in depression.  
 
PSYCHOMOTOR RETARDATION 
Psychomotor retardation is defined as a slowing-down of thought and physical movements. 
It is ubiquitous during infections (86, 87), and can be readily induced by even mild 
inflammatory challenges (88). It is also a cardinal symptom of depression (89) and a notable 
feature in a sub-set of patients with schizophrenia. In rodents, systemic inflammation 
consistently suppresses locomotor activity resulting in increased periods of immobility (90). 
IL-6 is strongly implicated in these motor-suppressing effects, which are reduced in IL-6 
knockout mice (91) and following blockade of IL-6 signaling (92, 93). 
In humans, low-level inflammation has been shown to selectively modulate substantia nigra 
reactivity during both low-level button press and more challenging color word Stroop tasks 
(88). Corroborating effects in rodents, this study also showed a tight correlation between 
induced changes in circulating IL-6 and motor response slowing across both congruent and 
incongruent Stroop trials suggesting an action on low-level pre-cognitive processes. Changes 
in IL-6 and left substantia nigra responses also predicted individual sensitivity to 
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inflammation-induced motor slowing. This association between IL-6 and poorer 
performance on simple and choice movement time tasks has subsequent been replicated in 
MDD patients (94).  
This finding is noteworthy as the substantia nigra is the major source of dopamine within the 
brain. Projections to the striatum play a critical role in facilitating movement (95) and  
modulating motor responses to stimulus salience (96); they are also linked to inflammation-
associated reductions in novelty salience (97). Lower striatal dopamine transporter activity is 
also linked to slower motor responses in the healthy elderly (98), and lower striatal 
presynaptic dopamine is reported in patients with depression and psychomotor retardation 
but not anxiety (99). Recently, psychomotor slowing in depression has also been linked to 
lower left basal ganglia glutamate (the other major neurochemical input to the striatum) and 
higher plasma and CSF C-reactive protein (CRP)  (100). 
Together, these studies support a central role for ascending dopaminergic (substantia nigra) 
and descending glutamatergic inputs into the dorsal striatum in psychomotor retardation 
associated with both inflammation and depression. During infection, slowing of 
psychomotor responses likely facilitates immune function by preserving energy and 
conserving heat. The convergence of findings across depression and inflammation suggests 
that chronic activation of these mechanisms may differentiate patients presenting with 
predominantly psychomotor or anxiety symptoms. 
 
SLEEP 
Pro-inflammatory cytokines (particularly IL-1 and TNF) are sleep regulatory agents that 
modulate slow wave sleep (101). During neuronal activity, co-release of ATP which acts on 
microglial P2X7 receptors to induce IL-1 and TNF release is believed to provide a potential 
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mechanism for enabling the brain to track prior usage history (102). During systemic 
inflammation, dynamic interactions between peripheral and central cytokines potentiate the 
effects of IL-1 and TNF on sleepiness, duration of non-REM sleep and slow wave power 
(102). Vagotomy attenuates some of these actions in rodents supporting a role for neural 
interoceptive pathways in mediating the effects of inflammation on non-REM sleep (103). 
Sleepiness and disrupted sleep are common features of many human inflammatory 
disorders (101) and are observed following acute inflammatory challenge (104) 
demonstrating the importance of interoceptive signaling in regulating sleep in response to 
systemic inflammation. Conversely, sleep also mediates susceptibility to infection during 
exposure to airborne respiratory viruses, further demonstrating the bidirectional nature of 
immune-brain communicatory pathways (105). 
Sleep disturbance is also an important risk factor for depression (106-108) conceivably 
because it increases inflammation (109-111), which as discussed above, likely plays a causal 
role in some forms of psychiatric illness. Perhaps because the vagus nerve is involved in the 
processing of sleep signals (112), depressed subjects with sleep disturbance have 
interoceptive deficits such as reduced accuracy in their perception of their heart beats but 
increased subjective perception of interoceptive sensitivity (113). Conversely, high cardiac 
vagal control, as evidenced by high resting heart-rate variability, has been reported to be 
associated with better subjective and objective sleep quality in healthy women (114). 
 
MEMORY 
Microglia and inflammatory cytokines influence a number of processes critical to learning 
and memory including long-term potentiation (LTP), synaptic plasticity and neurogenesis. In 
health these immunological processes support the remodeling of neural circuits to promote 
learning and memory (3, 31). However, during systemic inflammation interoceptive signaling 
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can disrupt this positive regulatory function, impairing memory. Typically this memory 
impairment is mild and reversible (115), however when inflammation is chronic or severe it 
can lead to accelerated age-related cognitive decline (116) or even persistent cognitive 
impairment (117). Medial temporal lobe (MTL) structures appear particularly sensitive to 
systemic inflammation. This may reflect their higher BBB permeability (118) and pro-
inflammatory cytokine receptor expression leading to heightened humoral interoceptive 
signaling (119, 120), or alternately their connectivity to insula (121) and consequent 
sensitivity to neural interoceptive signaling  (115).  
In rodents, peripheral inflammation induces IL-1 expression within the MTL (122) and 
replicates many of the direct actions of inflammatory cytokines on MTL-dependent memory 
including impaired spatial memory (3). In humans, naturalistic and experimental 
inflammatory challenges are associated with acute (reversible) impairment in spatial, verbal 
and nonverbal declarative memory (115, 123, 124). These effects are restricted to MTL-
dependent memory i.e. they do not perturb procedural memory and appear to be mediated 
via actions of inflammation on MTL glucose metabolism (115). However, when inflammation 
is chronic it has been linked to reductions in hippocampal volume (125, 126). This has 
important implications for psychiatry, particularly the neuropathology of depression, which 
is associated with both raised inflammatory markers and reduced hippocampal volume (127, 
128). Furthermore, MTL-dependent episodic memory impairment is one of the most 
commonly observed cognitive deficits in depression (129-131). Future studies will need to 
better understand the molecular mechanisms through which sustained interoceptive 
signaling of peripheral inflammation leads to persistent changes in MTL structure, determine 
whether modifiable factors can reverse this process, and clarify the significance of this link 
to the pathophysiology of inflammation-associated depression.  
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TREATMENT IMPLICATIONS 
Above, we have highlighted the diverse interoceptive pathways recruited during the central 
signaling of inflammation and its subsequent impact on regional neuronal function and 
behavior. Identification of the molecular and cellular mechanisms that mediate these effects 
is revealing novel therapeutic targets and leading to a reappraisal of how some established 
therapies might exert therapeutic efficacy. 
Perhaps the clearest example of a therapy directly targeting interoceptive mechanisms is 
vagal nerve stimulation (VNS), which exhibits potent anti-depressant properties (132). 
Though its mode of action is still only partially understood, it is now believed that actions on 
visceral afferent fibers at least partially underlie its clinical efficacy. However, VNS also 
modulates the efferent arm of the inflammatory reflex, inhibiting peripheral TNF, IL-1, and 
IL-6 production in humans (133). This anti-inflammatory action results in a reduction in 
circulating cytokines and consequently reduces signaling via humoral interoceptive 
pathways. Prolonged VNS also increases the firing rate of both serotoninergic, and 
noradrenergic neurons in the brainstem that are each implicated in the pathophysiology of 
depression (134). It remains to be clarified how many of these effects are achieved through 
modulation of interoceptive signaling of inflammation. 
Another strategy adopted in depression is the use of ‘anti-cytokine’ therapies to block 
cytokine signaling across interoceptive pathways. These agents (e.g. anti-TNF therapies) 
powerfully reduce circulating cytokine levels. Despite being unable to cross the BBB, they 
also reduce depressive symptoms suggesting an action through inhibition of interoceptive 
signaling (135, 136). Consistent with this, anti-depressant effects appear limited to 
individuals with raised inflammatory markers and by extension, interoceptive signaling of 
inflammation (135). Other approaches e.g. the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) target specific interoceptive mechanisms. During systemic inflammation, cytokines 
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act on the brain endothelium to trigger release of lipophilic prostaglandins that readily 
diffuse across the BBB to exert central effect (35). By inhibiting prostaglandin production 
NSAIDs block this interoceptive-signaling pathway. In the context of acute inflammation they 
alleviate flu-like symptoms; meta-analysis also suggests efficacy in patients with depression 
(137), though this remains controversial with some studies even suggesting worsening of 
depressive symptoms (138). This will need careful evaluation in future larger scale clinical 
trials. 
Another strategy is to target microglia, which appear central to transducing interoceptive 
signaling of peripheral inflammation into changes in neural function. One example of a 
microglial active agent is minocycline, a tetracycline antibiotic that readily crosses the BBB 
and inhibits microglial activation in rodents (77). Minocycline has demonstrated anti-
depressant properties in pre-clinical studies, in an open-label trial for bipolar depression (78) 
and in a recent randomized controlled trial of adjunctive treatment of MDD (79). It also has 
reported efficacy for negative symptoms in schizophrenia (80). However, minocycline has 
many additional actions that limit mechanistic interpretation of these studies (139). An 
alternative target is microglial P2X7 receptors that govern microglial IL-1 release and can 
modulate CNS chemokines, glutamate, and nitric oxide (140). In preclinical studies P2X7 
knockout mice show a protective phenotype in models of depression. However, further 
human in vivo trials are needed to test its therapeutic effects in depression and characterize 
phenotypes that may be most conducive to this therapeutic approach. 
 
SUMMARY 
The immune system is a diffuse sensory ‘organ’ that uses parallel neural, humoral and 
cellular pathways to communicate peripheral immune signals to the brain. However, the 
immune system does not act in isolation. Top down influences from the brain can dampen 
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or even prime peripheral immune responses. In the latter case this appears to provide a 
form of innate immune memory for previous stress exposure, which then utilizes cellular 
interoceptive mechanisms to heightened behavioral responses in the face of subsequent 
stress. Though adaptive in the short term, when immune activation is prolonged or severe or 
occurs in specific neurodevelopmental contexts it can give rise to psychiatric disorders such 
as depression, schizophrenia, and ASD. Developing understanding of the complexity of these 
interacting communicatory pathways is rapidly forcing a broadening of how we 
conceptualize interoception. It is also motivating the development and repurposing of novel 
immunotherapeutic agents potentially heralding an exciting new era of immunotherapies 
for use in psychiatry. 
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TABLE 1: Human imaging studies linking inflammation to regional changes in brain 
structure/function 
 
 Publications Participants Technique 
Neural 
interoception: 
Insula 
Rosenkranz 2005 (72) 
Harrison 2009 (19) 
Hannestad 2012 (18) 
Harrison 2015 (20) 
Harrison 2015 (20) 
Lekander 2016 (141) 
6 (WS) 
16 (WS) 
9 (WS) 
20 (WS) 
20 (WS) 
48 (BS) 
fMRI 
fMRI 
FDG PET 
FDG PET 
qMT 
rs-fMRI 
Reward: 
Ventral Striatum Eisenberger 2010 (73) 
Capuron 2012 (53) 
Haroon 2014 (54) 
Harrison 2016 (77) 
Felger 2016 (39) 
39 (BS) 
28 (BS) 
31 (BS) 
24 (RM) 
48 (correlation) 
fMRI 
F-DOPA-PET 
MRS 
fMRI 
rs-fMRI 
Memory: 
Medial temporal 
lobe 
Marsland 2008 (126) 
Harrison 2014 (115) 
Raz 2014 (142) 
Satizabal 2012 (143) 
Baune 2012 (144) 
76 (correlation) 
20 (RM) 
80 (correlation) 
1841 (correlation) 
303 (correlation) 
sMRI 
FDG-PET 
sMRI 
sMRI 
sMRI 
Psychomotor 
slowing: 
Substantia nigra 
Brydon 2008 (88) 16 (RM) 
 fMRI 
 
Participants: Study design is reported as: WS – Within Subject, BS – Between Subject, 
Correlation – correlational analysis. Technique: fMRI (functional MRI), FDG PET 
Fluorodeoxyglucose PET, qMT (quantitative Magnetization Transfer MRI), rs-fMRI (resting 
state functional MRI), sMRI (structural MRI).     
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FIGURE LEGENDS 
Figure 1: Peripheral Inflammation activates a neurally mediated interoceptive pathway 
Convergent data from diverse imaging techniques show that peripheral inflammation 
activates a neurally mediated interoceptive pathway projecting to insula. A) Mild pro-
inflammatory challenge using the Typhoid vaccine model increases BOLD signal within the 
human interoceptive brain regions including lateral thalamus (encompassing basal and 
posterior ventromedial nuclei (VMb and VMpo)) and cortical projections to dorsal 
mid/posterior and anterior insula within 3 hours of challenge (Modified from 19 with 
permission). B) LPS-induced peripheral inflammation increases Fluorodeoxyglucose (FDG) 
uptake with ventrolateral thalamus and posterior and anterior insula within 2 hours of 
inflammatory challenge (Modified from 18 with permission). C) Mild inflammation (induced 
using Typhoid vaccination) increases mid/posterior insula FDG-Glucose uptake (lower figure) 
and magnetization transfer from molecular-bound to free water (upper figure) within 4 
hours of inflammatory challenge (Modified from 20 with permission).  
 
Figure 2: ‘Circuit’ diagram illustrating visceral, humoral and cellular interoceptive signaling 
pathways and the major points of interaction 
 
Figure 3:  Role of humoral interoceptive pathways in anxiety and depressive-like behavior 
A) During homeostatic conditions neuron-derived regulatory factors, such as CX3CL1 and 
TGFβ maintain microglia in a ‘resting’ state. Low levels of effector monocytes circulate in the 
blood patrolling for pathogens or tissue damage and a small number of brain macrophages 
reside in the perivascular space to sample the brain microenvironment. B) During severe 
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psychosocial stress microglia respond to damage-associated molecular patterns (DAMPs) 
and elevated ATP released from neurons to adopt an ‘activated’ phenotype. Simultaneous 
increase in sympathetic output results in an increase in circulating monocytes and 
consequently brain macrophages. These monocytes are believed to traffic to stress-
associated brain regions and amplify pro-inflammatory responses through humoral 
interoceptive pathways involving vascular endothelial IL-1 receptor type-1 signaling. 
Modified from (145) with permission) 
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